Arcturus Therapeutics Holdings Inc (ARCT)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arcturus Therapeutics Holdings Inc chart...

About the Company

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

Exchange

NASDAQ

Website

arcturusrx.com

$358M

Total Revenue

184

Employees

$974M

Market Capitalization

-18.36

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ARCT News

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

14d ago, source: Zacks.com on MSN

Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s ...

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts

7d ago, source:

The 12-month price targets, analyzed by analysts, offer insights with an average target of $63.25, a high estimate of $87.00, ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript

10d ago, source: InvestingChannel on MSN

March 7, 2024 Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were ...

Arcturus Therapeutics Holdings Inc

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

11d ago, source:

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company ...

Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments

11d ago, source:

Operating Expenses: Increased to $245.0 million in 2023 from $193.8 million in 2022. Net Loss: Reported a net loss of $26.6 ...

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript

11d ago, source: Seeking Alpha

Greetings and welcome to the Arcturus Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

14d ago, source: Nasdaq

Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s growth of 10.5%. Last month, the European Commission granted orphan ...

Arcturus Therapeutics Holdings Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call

10d ago, source: Yahoo Finance

Neda Safarzadeh; VP of IR, Public Relations, and Marketing; Arcturus Therapeutics Holdings, Inc. Joe Payne; President and CEO; Arcturus Therapeutics Holdings, Inc ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...